Skip to main content
  • Jul 25, 2025

    Edwards Lifesciences loses TAVR leader to robotics firm, announces replacement

    Cardiovascular Business

    Michael Walter |  | Cardiovascular Business | TAVR
    Larry Wood

    Larry Wood

    Larry Wood, a veteran medtech executive who spent years with the transcatheter aortic valve replacement (TAVR) division at Edwards Lifesciences, has been named the new president and CEO of Procept BioRobotics. His term begins on Sept. 2.

    Procept BioRobotics is a surgical robotics company focused on the urology market. The company’s portfolio includes the Hydros Robotic System, an artificial intelligence-enabled robotic system that delivers Aquablation treatments for the treatment of benign prostatic hypertrophy.

    “I am honored to join Procept BioRobotics at such a pivotal time in the company’s growth,” Wood said in a statement. “The company’s innovative approach to treating prostate disorders has the potential to transform the standard of care for patients worldwide. I look forward to leading this exceptional team and building on their many successes to continue to improve treatment outcomes for doctors and their patients.”

    Wood spent several years with Edwards Lifesciences, holding a variety of roles. He worked as president of the company’s TAVR and surgical structural heart divisions since 2023. 

    Edwards Lifesciences to replace one TAVR veteran with another

    During a July 24 earnings call, Edwards Lifesciences announced that Dan Lippis, a corporate vice president who has been with the company since 2010, will be stepping in to replace Wood as head of the TAVR division. 

    Lippis already has years of experience with the Edwards Lifesciences TAVR portfolio and once ran the company’s TAVR division in Europe. He and Wood are expected to work together closely to allow for a smooth transition. 

    Transition comes at a momentous time for the Sapien 3 TAVR platform

    At the same earnings call, Edwards Lifesciences announced that sales were up significantly in the second quarter, driven in part by the success of the company’s balloon-expandable Sapien 3 TAVR platform. In May, the U.S. Food and Drug Administration (FDA) approved multiple Sapien 3 valves for the treatment of asymptomatic severe aortic stenosis, a first for any TAVR technology. 

    “This approval is a powerful opportunity to streamline patient care and improve the efficiency of the healthcare system,” Wood said at the time. “We are proud to partner with leading physicians to advance our knowledge of this deadly disease with high quality science and optimize the treatment pathway for patients.”

    Related TAVR Content:

    Balloon-expandable, self-expanding TAVR valves associated with comparable long-term outcomes
    Boston Scientific pulls plug on TAVR devices after failing to gain FDA approval
    Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes
    A victory for early treatment: FDA approves first TAVR valves for asymptomatic severe aortic stenosis
    Michael Walter
    Michael Walter, Managing Editor

    Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details